Colorectal cancer (CRC) is one of the most common cancers and one of the leading causes of cancer death in the Western world. The disease arises from the accumulation of mutations in oncogenes, tumor suppressor genes and mismatch repair genes during progression from normal colon epithelium to adenoma and metastatic carcinoma. The majority of colorectal cancers arise in sporadic form. About one-third of patients with CRC have a family history of cancer and elevated risk for this malignant disease. However, only 5% of CRC arise from a germline mutation in high penetrant genes, adenomatous polyposis coli (APC) gene and DNA mismatch repair (MMR) genes. The most common hereditary CRC syndrome is Lynch syndrome defined by hereditary germline mutations in one the of MMR genes. The term hereditary non-polyposis colorectal cancer (HNPCC), previously used interchangeably with Lynch syndrome, now refers to a broader spectrum of familial CRC disorders that can mimic some clinical features of Lynch syndrome, but without germline mutations in MMR genes characteristic for Lynch syndrome. Distinguishing between the HNPCC disorders is important for clinicians, as the approach to surveillance for patients and their family members differs according to risk for CRC associated with each syndrome.
Rad 530. Medical Sciences, 44(2017) : 73-79 S. Kapitanović: Molecular stratification of sporadic and hereditary colorectal cancer -mini review from normal colorectal epithelium to adenoma and metastatic carcinoma ( Figure 1 ) [2] . Colorectal cancer is a genetic disease that might be influenced by the local colorectal environment, individuals's genetic profile as well as by hereditary germline mutations [3, 4] .
The majority of colorectal cancers (75-80%) arise in sporadic form without known contribution from germline mutations and only 20-25% of the patients have a family history of CRC. However, only 5% of CRC arise from a germline mutation in high penetrant genes, adenomatous polyposis coli (APC) gene (1%) and MMR genes (3-5%) while the remaining CRCs have a positive family history but cannot be categorized to any hereditary CRC syndrome. These familial CRC are caused by single nucleotide polymorphisms (SNP) in less penetrant genes such as cytokines. Many susceptibility loci have been identified, however, their value in CRC risk prediction remains low [5, 6] .
The development of colorectal cancer is a multistep process caused by progressive accumulation of genetic and epigenetic changes that cause activation of oncogenes and/or inactivation of tumor suppressor genes. The earliest trigger is the mutation of the APC (Adenomatous Polyposis Coli) gene. Mutations in oncogenes (KRAS) and tumor suppressor genes (p53, DPC4) as well as mutations and epigenetic changes in MMR (MisMatch Repair) gene drive tumor towards malignant transformation and metastasis. [3, 5, [7] [8] [9] .
Sporadic CRC can be divided into two groups: hypermutated (16% of sporadic CRC) and nonhypermutated (84% of sporadic CRC). The etiology of hypermutated tumors is largely driven by the presence of microsatellite instability (MSI) as a result of mutations in mismatch repair (MMR) genes, specifically somatic hypermethylation of hMLH1 gene. Nonhypermutated sporadic CRC is driven by mutations described as adenoma carcinoma sequence including APC, KRAS and p53 gene mutations. BRAF gene is most frequently mutated in hypermutated tumors than APC is mutated in both groups of sporadic CRC, what is in accordance with its role as a gatekeeper mutation in CRC [3, [10] [11] [12] . The results of research studies also characterized 3 molecular pathways that highlight CRC development and progression: MSI (wholly within the hypermutated group), chromosomal instability (CIN; wholly in the nonhypermutated group) and CpG island methylator phenotype (CIMP; within both the hypermutated and nonhypermutated group) [3] .
The level and nature of inflammation in primary CRC may be complex, but the type, density and intratumor location of immune cells can predict patient survival, often better than classical staging [13] . This same inflammation has been associated with initiating alterations involving specific tetranucleotide microsatellite DNA sequences, termed "elevated microsatellite alterations at selected tetranucleotide S. Kapitanović: Molecular stratification of sporadic and hereditary colorectal cancer -mini review repeats" or EMAST caused by loss of the DNA MMR complex function due to a nucleus-to-cytosol shift of its component hMSH3 protein. EMAST can be identified in up to 60% of CRCs making this biomarker more common than MSI high (MSI-H) [14] . The presence of EMAST in primary CRCs predict advanced-stage disease in patients and is associated with poor survival over patients with EMAST negative CRC tumors. EMAST can modulate all 3 (MSI-H, CIN and CIMP) pathways in sporadic CRC tumorigenesis and is a biomarker linked to advanced, metastatic stage and poor survival in both groups, hypermutated and nonhypermutated sporadic colorectal cancer [15, 16] .
About one-third of patients with colorectal cancer have a family history of cancer but only 5% of all patients with CRC have identified hereditary mutations in genes that regulate growth processes in colonic cells. The most common hereditary CRC syndrome is Lynch syndrome identified and defined by hereditary germline mutations in one of the DNA mismatch repair (MMR) genes (MSH2, MLH1, MSH6, PMS2) and is transmitted in an autosomal dominant fashion [17] . Mismatch repair proteins form a complex that detects and corrects replication errors. A deregulated MMR system due to the mutations in MMR genes leads to accelerated accumulation of somatic mutations, often resulting in carcinogenesis. The two most commonly mutated MMR genes, MSH2 and MLH1, account for approximately 90% of mutations found in Lynch syndrome patients, with the remaining 10-30% distributed equally in MSH6 and PMS2 [17] [18] [19] .
Microsatellite instability (MSI) is the molecular marker of MMR genes mutations and DNA mismatch repair deficiency. Additionally, the use of immunohistochemistry to detect expression of DNA MMR proteins in tumor tissue is highly comparative to MMR function. The finding of MSI and/or absence of DNA MMR protein expression identifies that a tumor has lost DNA MMR function, and is the basis for differentiating familial CRC cases associated with Lynch syndrome from other HNPCC conditions [19] [20] [21] [22] .
The term hereditary non-polyposis colorectal cancer (HNPCC), previously used interchangeably with Lynch syndrome, now refers to a broader spectrum of familial CRC encompassing disorders that can mimic some clinical features of Lynch syndrome, but without germline mutations in MMR genes characteristic for Lynch syndrome. Distinguishing between the HNPCC disorders is important for clinicians, as the approach to surveillance for patients and their family members differs according to risk for colonic and extracolonic cancers associated with each syndrome [18, 19, 23] .
Lynch-like syndrome is HNPCC condition associated with CRC tumors with two somatic mutations in one of the MMR genes in the tumor, but no germline Limited published data suggests that Lynch-like syndrome patients have a similar age of onset of CRC but lower incidence of extra-colonic cancers compared to patients with Lynch syndrome [4, 24] .
Familial colorectal cancer type X (FCCTX) is HNPCC condition associated with CRC tumors negative for MSI and germline mutations in MMR genes. Clinically, FCCTX is associated with a twofold increased risk of CRC compared to the general population but without an increased risk of extra colonic cancers [4, 22, 23] .
Polymerase proofreading associated polyposis syndrome (PPAP) is a rare autosomal dominantly inherited syndrome in which the exonuclease domain of POLE (encoding DNA polymerase e) or POLD1 (encoding DNA polymerase d1) is mutated in the germline. Two highly penetrant mutations are described (POLE p.Leu424Val and POLD1 p.Ser478Asn) [25] . Individuals with germline POLE mutations exhibit colonic oligopolyposis (generally between 5-70 adenomas) as early as 20 years of age, CRCs, and duodenal adenomas and carcinomas. POLD1 mutation carriers exhibit colonic oligopolyposis (generally 3-50 adenomas) and CRC as young as 20 years of age as well, but in addition exhibit increased risk for endometrial cancers and brain tumors [19, 25] . Although CRCs from PPAP patients are hypermutated or ultramutated due to loss of polymerase function these tumors are microsatellite stable and do not exhibit loss of expression of MMR proteins [10, 25] .
The opportunity to prevent the occurrence of and mortality from hereditary colorectal cancer is maximized by the recognition of clinical features of each syndrome, an accurate risk assessment with genetic testing and appropriate screening and surveillance. Collaboration between primary care providers, gastroenterologists, colorectal and other surgeons, pathologists, oncologists, and genetic specialists is the optimal approach to care for patients and families with hereditary colorectal cancer [23] .
Modern molecular platforms give the ability to characterize tumors at multiple levels and to define molecular and biological subtypes of cancer. Cancers could be divided into subtypes that are more or less aggressive. Identification of a more aggressive subtype may influence the type of their treatment. Molecular stratification and sub classification of tumors will add a step to traditional clinical practice and better diagnosis and therapy of different types of cancer as well as colorectal cancer [26] .
Optimization of molecular genetic testing to predict the risk for developing cancer, to diagnose a disease at an early stage, to give a prognosis, and predict treatment response is of great importance to the patients as well as to the health professionals.
